• news

• News in Israel

• health

Lowering the age of breast cancer tests and a cure for Alzheimer's: The drug basket committee begins work

The committee will convene for its first meeting in 2022, when it will submit its recommendations to Minister Horowitz this coming December.

What diseases will the committee focus on, what are the prominent treatments that will be discussed and who are the people who make it up?

all the details

Tags

• Nitzan Horowitz

• cancer

• Health basket

Meirav Cohen

Sunday, 24 October 2021, 06:22 Updated: 06:24

• Share on Facebook

• Share on WhatsApp

• Share on general

• Share on general

• Share on Twitter

• Share on Email

0 comments

The Medicines Basket Committee will convene today (Sunday) for its first meeting for 2022 at the Ministry of Health at Sheba Medical Center in Tel Hashomer, headed by Professor Yonatan Halevi, President of Shaare Zedek Medical Center. The committee is expected to complete its work this coming December and submit its recommendations to Health Minister Nitzan Horowitz. The first meeting will also be joined by Minister Horowitz and the Director General of the Ministry of Health, Prof. Nachman Ash

. City will sit on the committee alongside former MKs, medical professionals from various hospitals and economists.

The most prominent treatments on the agenda for the 2022 health basket are in the field of oncology, cancer research: "Libtio" - for non-melanoma skin cancer;

"Anharto" - for metastatic breast cancer;

"Tagriso" - for early-stage lung cancer and "Impenza" for small cell lung cancer.

In other areas, there are "Dupixant" treatments - for those suffering from Manzal polyposis (chronic sinusitis) and "Forsythe" - for patients with kidney failure.

More on Walla!

Blue and white breakthrough: A new Israeli drug will increase the life expectancy of lung patients

To the full article

The committee will submit its recommendations to him this coming December.

Minister Horowitz (Photo: Flash 90, Yonatan Zindel)

Lung cancer is the leading cause of death among all malignancies.

Every year about 2,600 new patients are discovered and 1,600 die from the disease.

More than half of the patients are diagnosed with advanced stages of the disease as its symptoms are not specific.

13% of patients with NSCLC carry the KRAS G12C mutation, which is considered to be particularly common and deadly, but to date the treatment options for patients in advanced stages have been limited and limited.

The drug is expected to be joined by the drug LUMAKRAS, which has shown good efficacy when 80.6% of patients have control of the disease - a contraction in the tumor or at least a halt in the progression of the tumor has been observed.

Women are invited to perform publicly funded mammograms from the age of 50 - but 25% of patients are diagnosed at a younger age (Photo: Reuven Castro)

This year, as in the last five years, the committee will raise the age of mammography tests from 50 to 40. Breast cancer is the most common malignant disease among women in Israel and the Western world alike, and is the number one cause of death among women.

More than 5,400 women are diagnosed with breast cancer each year in Israel, 25% of them are young under the age of 50, which is about 1,300 new women under the age of the test. The social significance is also comprehensive - since these are young women, the harm to families, children and the economy is more felt. However, 92% are cure rates at early detection of the disease, so the significance of early breast cancer detection allows most women to receive treatment, recover from the disease, get back to living their lives normally and function at their best.

The most effective way to detect breast cancer early is by performing screening tests, with a mammogram being the only screening test whose effectiveness in early diagnosis is research proof among women at normal risk.

In Israel, women are invited to undergo a publicly funded mammogram from the age of 50 and up, in accordance with the recommendations of the Ministry of Health, while in practice, about 25% of patients are diagnosed under the age of 50.

The most prominent treatments on the agenda for the Health Basket 2022: A Cure for Metastatic Breast Cancer and Lung Cancer (Photo: ShutterStock)

The committee's deliberations will also include a cure for Alzheimer's.

Between 80,000 and 100,000 people in Israel suffer from Alzheimer's - a progressive neurological disease, which leads to mental deterioration characterized by memory loss, confusion and disorientation and eventually leads to death.

To date, there have been no treatments that change the course of the disease, only supportive and symptom-oriented treatments, with the burden of a person with Alzheimer's on family members and other circles of support becoming heavier as the disease progresses.

ADUHLEM is a drug designed to delay the clinical deterioration in early-stage Alzheimer's patients.

Studies have shown a slowdown in deterioration in many parameters such as ability to perform daily activities, networking and memory.

• Share on Facebook

• Share on WhatsApp

• Share on general

• Share on general

• Share on Twitter

• Share on Email

0 comments